Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis

Published:2024-02-12 Issue:1 Volume:46 Page:
ISSN:0886-022X
Container-title:Renal Failure
language:en
Short-container-title:Renal Failure

Author:

Tian Lei¹,Wang Mengdi¹,Liu Mengchao¹^ORCID,Pang Yanyu¹,Zhao Jingwen¹,Zheng Bingjie¹,Wang Yutong¹,Zhao Wenjing¹

Affiliation:

1. Department of Nephrology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China

Funder

The National Natural Youth Science Foundation of China

The National Natural Science Foundation of China

Beijing Municipal Cultivation Program

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/0886022X.2024.2313864

Reference55 articles.

1. Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis

2. Association of Mortality and Hospitalization with Achievement of Adult Hemoglobin Targets in Adolescents Maintained on Hemodialysis

3. Left Ventricular Geometry in Children with Mild to Moderate Chronic Renal Insufficiency

4. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics

5. Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of hypoxia-inducible factor 1 in type 1 diabetes;Trends in Pharmacological Sciences;2024-09

2. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease;Biomedicines;2024-08-18

3. What is the impact of anemia pharmacotherapy on chronic kidney disease progression?;Expert Opinion on Pharmacotherapy;2024-07-02